Live feed02:30:00·1555dPRReleasevia QuantisnowOxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines' established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. with Homology Medicines as 20% ownerByQuantisnow·Wall Street's wire, on your screen.FIXX· Homology Medicines Inc.Health Care